1.Intravitreal Triamcinolone Reinjection for Refractory Diabetic Macular Edema.
Alireza RAMEZANI ; Hamid AHMADIEH ; Homa TABATABAEI
Korean Journal of Ophthalmology 2006;20(3):156-161
PURPOSE: To evaluate the effect of intravitreal triamcinolone acetonide (IVT) reinjection on clinical and optical coherence tomographic features in refractory diabetic macular edema. METHODS: In a prospective interventional case series, all IVT treated patients enrolled in a previous clinical trial were recalled to have a new ophthalmologic examination and optical coherence tomography (OCT) performed. Eyes found suitable for reinjection received 4 mg IVT. Complete clinical examination and OCT were repeated at 2 and 4 months post-injection. The changes were statistically analyzed using a paired t test and were compared to the results of the first injections. RESULTS: Of all returning patients, 12 cases with complete records were considered candidates for reinjection. Visual acuity (VA) changes were not significant after the first and second interventions, although there was a relative improvement (0.14 logMAR) 2 months after the first injection. Reductions of central macular thickness (CMT) were 43+/-69 micrometer, and 40+/-69 micrometer after the first injection and 27+/-48 micrometer, 49+/-58 micrometer after the reinjection at 2 and 4 months, respectively. None of the mentioned changes was significant. After the second injection, however, intraocular pressure was elevated at both 2 and 4 months (3.6 and 2.4 mmHg respectively, P<0.05). Two months after the first administration, intraocular pressure was found to be raised significantly (5.58 mmHg, P=0.001). CONCLUSIONS: The transient beneficial effects of IVT on diabetic macular edema are not repeated with second injections. However, IVT-related ocular hypertension is more persistent after reinjection.
Vitreous Body
;
Visual Acuity
;
Triamcinolone/*administration & dosage
;
Treatment Outcome
;
Tomography, Optical Coherence
;
Time Factors
;
Retreatment
;
Prospective Studies
;
Male
;
Macular Edema, Cystoid/*drug therapy/etiology/pathology
;
Intraocular Pressure
;
Injections
;
Humans
;
Glucocorticoids/*administration & dosage
;
Follow-Up Studies
;
Female
;
Diabetic Retinopathy/*complications/pathology
2.Resolution of Severe Macular Edema in Adult Coats' Disease with Intravitreal Triamcinolone and Bevacizumab Injection.
Jong Hwa JUN ; Yu Cheol KIM ; Kwang Soo KIM
Korean Journal of Ophthalmology 2008;22(3):190-193
A 47 year old male patient visited our hospital with the chief complaint of deterioration of the visual acuity in the left eye. The fundus examination revealed thick hard exudates, multiple aneurysms and telangiectasias of the retinal vessels in the posterior pole. Fluorescein angiography demonstrated massive leakage over an area of the aneurysms. Optical coherence tomography (Stratus OCT; Zeiss-Humphrey, Dubin, CA) revealed diffuse and marked thickening of the retina. Laser photocoagulation was performed under the diagnosis of Coats' disease. However, the treatment could not be performed satisfactorily. On the first and 6th weeks, an intravitreal injection of bevacizumab and triamcinolone acetonide was administered, and laser photocoagulation was again attempted. The effectiveness of eachagent on retinal edema was evaluated at the follow-up performed at 1, 2, 5, 7, 10 weeks and 6 months after the injection. At one week after the intravitreal bevacizumab injection, there was no improvement. An intravitreal injection of triamcinolone acetonide was performed 6 weeks after the initial diagnosis,which resulted in a reduction in the thickness of the macular edema. Therefore, laser photocoagulation was performed sufficiently on telangiectasias. The follow-up at 6 months showed a relative increase in the macular edema, but there was reduced leakage from the telangiectasias compared with the previous angiograph.
Angiogenesis Inhibitors/*therapeutic use
;
Antibodies, Monoclonal/*therapeutic use
;
Drug Therapy, Combination
;
Fluorescein Angiography
;
Glucocorticoids/*therapeutic use
;
Humans
;
Injections
;
Laser Coagulation
;
Macular Edema/*drug therapy/etiology
;
Male
;
Middle Aged
;
Retinal Diseases/complications/*drug therapy/surgery
;
Retinal Vessels/pathology
;
Telangiectasis/complications/*drug therapy/surgery
;
Tomography, Optical Coherence
;
Triamcinolone Acetonide/*therapeutic use
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Vitreous Body
3.Diabetic Macular Edema Before and After Intravitreal Triamcinolone Injection.
Alireza RAMEZANI ; Homa TABATABAIE ; Hamid AHMADIEH
Korean Journal of Ophthalmology 2007;21(2):95-99
PURPOSE: To compare intravitreal triamcinolone acetonide (IVT) versus natural course in refractory diabetic macular edema. METHODS: In a prospective interventional case series, twenty five eyes with refractory DME which had been allocated to the sham group of a previous clinical trial underwent new examination and optical coherence tomography about 9 months after their first enrollment. Twenty eyes that met the inclusion criteria, visual acuity (VA) < 20/50 and central macular thickness (CMT) > 200 micrometer, were treated by 4 mg IVT. Evaluations were repeated at 2 and 4 months post-injection to imitate the similar examination intervals after sham injection. Corrected visual acuity and macular thickness changes following IVT were compared to the corresponding changes after sham injection (the natural course). RESULTS: Visual acuity changes within and between each period were not statistically significant. Visual acuity decreased 0.08 & 0.09 logMAR by 2 months and 0.06 & 0.04 logMAR by 4 months after sham and IVT injections, respectively. The changes of macular thickness after IVT and sham intervention were not meaningful either. However, the difference between thickness changes by 4 months (52+/-50 micrometer increase after sham vs. 262+/-115 micrometer reduction after IVT) was significant (P=0.014). CONCLUSIONS: Concerning macular thickness, IVT has beneficial effect on refractory diabetic macular edema as opposed to observation. However, considering visual acuity, it does not induce significant difference in comparison to the natural course of the disease.
Diabetic Retinopathy/*complications/pathology
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Macula Lutea/drug effects/*pathology
;
Macular Edema/*drug therapy/etiology/pathology
;
Male
;
Middle Aged
;
Prospective Studies
;
Time Factors
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitreous Body
4.Diabetic Macular Edema Before and After Intravitreal Triamcinolone Injection.
Alireza RAMEZANI ; Homa TABATABAIE ; Hamid AHMADIEH
Korean Journal of Ophthalmology 2007;21(2):95-99
PURPOSE: To compare intravitreal triamcinolone acetonide (IVT) versus natural course in refractory diabetic macular edema. METHODS: In a prospective interventional case series, twenty five eyes with refractory DME which had been allocated to the sham group of a previous clinical trial underwent new examination and optical coherence tomography about 9 months after their first enrollment. Twenty eyes that met the inclusion criteria, visual acuity (VA) < 20/50 and central macular thickness (CMT) > 200 micrometer, were treated by 4 mg IVT. Evaluations were repeated at 2 and 4 months post-injection to imitate the similar examination intervals after sham injection. Corrected visual acuity and macular thickness changes following IVT were compared to the corresponding changes after sham injection (the natural course). RESULTS: Visual acuity changes within and between each period were not statistically significant. Visual acuity decreased 0.08 & 0.09 logMAR by 2 months and 0.06 & 0.04 logMAR by 4 months after sham and IVT injections, respectively. The changes of macular thickness after IVT and sham intervention were not meaningful either. However, the difference between thickness changes by 4 months (52+/-50 micrometer increase after sham vs. 262+/-115 micrometer reduction after IVT) was significant (P=0.014). CONCLUSIONS: Concerning macular thickness, IVT has beneficial effect on refractory diabetic macular edema as opposed to observation. However, considering visual acuity, it does not induce significant difference in comparison to the natural course of the disease.
Diabetic Retinopathy/*complications/pathology
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Macula Lutea/drug effects/*pathology
;
Macular Edema/*drug therapy/etiology/pathology
;
Male
;
Middle Aged
;
Prospective Studies
;
Time Factors
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitreous Body
5.Dose Dependent Effects of Intravitreal Triamcinolone Acetonide on Diffuse Diabetic Macular Edema.
Joon Sung BAE ; Sung Joon PARK ; I Rum HAM ; Tae Gon LEE
Korean Journal of Ophthalmology 2009;23(2):80-85
PURPOSE: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. METHODS: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 mg (n=12 eyes), 8 mg (n=17) or 25 mg (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. RESULTS: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. CONCLUSIONS: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg.
Adult
;
Aged
;
Aged, 80 and over
;
Diabetic Retinopathy/*complications/drug therapy/pathology
;
Dose-Response Relationship, Drug
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Intraocular Pressure
;
Macular Edema/diagnosis/*drug therapy/etiology
;
Male
;
Middle Aged
;
Retrospective Studies
;
Time Factors
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitreous Body
6.Intravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema.
Young Jae CHOI ; In Kyung OH ; Jae Ryung OH ; Kuhl HUH
Korean Journal of Ophthalmology 2006;20(4):205-209
PURPOSE: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. METHODS: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured. RESULTS: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection. CONCLUSIONS: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.
Vitreous Body
;
Visual Acuity
;
Triamcinolone Acetonide/*administration & dosage/therapeutic use
;
Treatment Outcome
;
Tomography, Optical Coherence
;
Prospective Studies
;
Orbit
;
Middle Aged
;
Male
;
Macular Edema, Cystoid/*drug therapy/etiology/pathology
;
Injections
;
Humans
;
Glucocorticoids/*administration & dosage/therapeutic use
;
Fundus Oculi
;
Follow-Up Studies
;
Fluorescein Angiography
;
Female
;
Diabetic Retinopathy/*complications/pathology
;
Aged